Michelle Dalton

Chasing Presbyopia Utopia

Chasing Presbyopia Utopia: Four Innovators and Their Search for Ophthalmology’s ‘Holy Grail’

The numbers can be overwhelming: 1.8 billion people globally were living with presbyopia in 2015, 826 million of whom had near vision impairment because they had no, or inadequate, vision correction.1 Further, the global unmet need for presbyopia correction stands around 45%.1 In the US, it is estimated 123 million...

Read More
What Relaxed Gene Therapy Oversight Means

Putting Relaxed NIH, FDA Oversight of Gene Therapies into Perspective

The first human gene therapy trial started in 1990, and over the course of that decade a multitude of questions about the safety and efficacy of this approach emerged. In 1999, a patient died during a safety trial of a gene therapy, leading to much greater scrutiny and increased regulatory...

Read More
MIGS Minus One: What’s Next?

MIGS Minus One: What’s Next?

With Alcon’s voluntary withdrawal in late August of the CyPass MicroStent due to safety concerns, many have been wondering how the rest of the class in the micro-invasive glaucoma surgery (MIGS) space will fare. Alcon is, after all, a major player and when it advises surgeons to “immediately cease further...

Read More
Dry Eye Panel Sees Promising Path Ahead

How Newer Diagnostics and Devices Are Making Dry Eye Treatments an Easier Sell

WASHINGTON, DC – Treating flairs and fluctuations while employing steroid tapering for the treatment of dry eye was the hot topic during the dry eye panel at OIS@ASCRS 2018. The consensus from panelists Sam Garg, MD (Gavin Herbert Eye Institute), Preeya Gupta, MD (Duke University Eye Center), and John Sheppard,...

Read More
Integrins Gain Traction in Ophthalmology

With Integrins, Necessity Really is the Mother of all Invention

Stopping growth factors that create damage in the eye has proven lucrative. Lucentis (ranibizumab, Roche/Genentech) achieved sales of $1.8 billion in 2016 outside the US alone, and $1.46 billion within the US. Making surgical treatments safer (as the minimally invasive glaucoma surgery [MIGS] devices do) has also proven lucrative –...

Read More
Dry Eye Newbie Xiidra Grabs Large Market Share

Dry Eye Newbie Xiidra Grabs Large Market Share

During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat – if any – it would pose to Allergan’s Restasis (topical cyclosporine 0.05%). With an estimated 30 million dry eye sufferers and only 1 million or...

Read More

Iconic Leader Allergan Has No Plans to Slow Down

CHICAGO—This year’s OIS Industry Tribute celebrated one of the best-known names in ophthalmology: Allergan. The Dublin-based company is one that “we rely on for innovation and growth and solving problems,” said William J. Link, PhD, who co-moderated the Tribute with William Meury, Allergan’s chief commercial officer. Allergan was founded by...

Read More
Aerie’s positive data keeps Wall Street happy

Aerie’s Positive Data Keep Wall Street Happy

Earlier this month, Aerie Pharmaceuticals filed its first NDA for once-daily Rhopressa (netarsudil) and released top-line data from its once-daily Roclatan (Rhopressa and latanoprost) Mercury 1 study; both of Aerie’s products are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. With Roclatan meeting its...

Read More
Can Ocular Therapies Diversify Biogen Portfolio? - Eye On Innovation Article - Healthegy

Can Ocular Therapies Diversify Biogen Portfolio?

Biotechnology company Biogen (Cambridge, MA) recently committed $20 million into a collaboration with the University of Pennsylvania to co-develop gene therapies using next-generation adeno-associated virus (AAV) gene delivery vectors, which have shown promise in early studies for treating a variety of retinal disorders. Biogen seems to be moving quickly into...

Read More
Mixing MIGS and Meds - Eye On Innovation Article

Mixing MIGS & Meds

Long gone are the days where glaucoma surgery meant an invasive procedure with the likelihood of a serious complication developing down the road – while trabeculectomy is still a viable option, its side-effect profile is relegating it to more of a final option. These days, surgeons are much more likely...

Read More
Highlights from AGS: New Surgical Devices, Novel Therapeutics - Eye on Innovation

Highlights from AGS: New Surgical Devices, Novel Therapeutics

This year’s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and surgery are designed to treat one of the primary risk factors – elevated IOP. But they are not designed to directly target the underlying degeneration...

Read More
Drugs & Devices for Dry Eye - Ophthalmology Innovation Summit 2015

2016 Promises to Disrupt Dry Eye

This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may deliver the biggest success. The company is close to bringing a second therapeutic to the market to treat dry eye conditions, as lifitegrast is currently...

Read More